Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance

1 Jan 2009

Abstract excerpt

BACKGROUND: In breast cancer, overexpression of the transmembrane tyrosine kinase ERBB2 is an adverse prognostic marker, and occurs in almost 30% of the patients. For therapeutic intervention, ERBB2 is targeted by monoclonal antibody trastuzumab in adjuvant settings; however, de novo resistance to this antibody is still a serious issue, requiring the identification of additional targets to overcome resistance. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19118495
DOI: 10.1186/1752-0509-3-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistancePMID 19118495Read ↗

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer TherapySemantic proximity Read ↗

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSemantic proximity Read ↗

Resistance to Anti-HER2 Therapies in Breast CancerSemantic proximity Read ↗

Lipid Metabolism Reprogramming and Trastuzumab Resistance in Breast Cancer Cell Lines Overexpressing the ERBB2 Membrane ReceptorSemantic proximity Read ↗

Lipid Metabolism Reprogramming Is Associated with Trastuzumab Resistance in ERBB2+ Breast Cancer Cell LinesSemantic proximity Read ↗

Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cellsSemantic proximity Read ↗

Sensitization of resistant cells with a BET bromodomain inhibitor in a cell culture model of deep intrinsic resistance in breast cancerSemantic proximity Read ↗

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerSemantic proximity Read ↗

OPTIMIZING THERAPEUTIC TARGETS FOR BREAST CANCER USING BOOLEAN NETWORK MODELSSemantic proximity Read ↗

Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to TrastuzumabSemantic proximity Read ↗

Modelling the role of dual specificity phosphatases in Herceptin resistant breast cancer cell linesSemantic proximity Read ↗

Precision Therapeutics in Triple-Negative Breast Cancer: Boolean Network Control and Pharmacological Mapping of Individualized ModelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.